Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

Comedian and Emmy-nominated actor Kym Whitley opens up about her long journey with weight management. The "Happy Gilmore 2" ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

Zepbound, a weight loss drug by Eli Lily, received FDA approval. How the tirzepatide-containing drug works, potential side effects, and insurance coverage.

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Nostalgic ’90s movie lovers will find it hard to forget classics like Mrs. Doubtfire, and even harder to forget Harvey ...

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a clinical trial show 20% of participants who took Zepbound achieved ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Novo Nordisk's weight-loss medication, Wegovy, uses semaglutide, which only focuses on GLP-1. That difference translated to greater weight loss with Zepbound than Wegovy, a recent study found.